Comparative Pharmacology
Head-to-head clinical analysis: UROVIST MEGLUMINE DIU CT versus VARIBAR PUDDING.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROVIST MEGLUMINE DIU CT versus VARIBAR PUDDING.
UROVIST MEGLUMINE DIU/CT vs VARIBAR PUDDING
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
Barium sulfate acts as a radiopaque contrast agent. It has high atomic number (z=56) and density, which attenuates X-rays and provides positive contrast in the gastrointestinal tract. It is not absorbed systemically and coats the mucosal surface, allowing visualization of luminal anatomy and pathology.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
125 mL orally once for upper GI studies; 250-500 mL orally once for small bowel follow-through. Not for IV use.
None Documented
None Documented
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Not applicable; barium sulfate is not absorbed systemically; gastrointestinal transit time is approximately 1–2 hours for gastric emptying and 6–24 hours for colonic passage.
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Varibar (barium sulfate) is not absorbed from the GI tract; it is excreted unchanged in feces. 100% fecal elimination as unabsorbed barium sulfate.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent